Early research (Phase 1)UnknownNCT04318964What this trial is testingTAEST16001 in the Treatment of Soft Tissue SarcomaWho this might be right forSoft Tissue Sarcoma Sun Yat-sen University 12
Early research (Phase 1)Looking for participantsNCT05473910What this trial is testingTSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationWho this might be right forAMLMyelodysplastic SyndromesALL, Adult TScan Therapeutics, Inc. 75
Testing effectiveness (Phase 2)Study completedNCT02960230What this trial is testingH3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasWho this might be right forDiffuse Intrinsic Pontine GliomaGliomaDiffuse Midline Glioma, H3 K27M-Mutant Sabine Mueller, MD, PhD 50
Early research (Phase 1)Looking for participantsNCT05877599What this trial is testingNT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H MutationWho this might be right forNon-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma+4 more AstraZeneca 46
Testing effectiveness (Phase 2)Looking for participantsNCT06840119What this trial is testingPhase 1/2 Study of IMC-R117C in Selected Advanced CancersWho this might be right forCancerHLA-A*02:01-positive Immunocore Ltd 600
Large-scale testing (Phase 3)Looking for participantsNCT06112314What this trial is testingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Who this might be right forAdvanced Melanoma Immunocore Ltd 680
Testing effectiveness (Phase 2)Looking for participantsNCT06942442What this trial is testingA Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell SarcomaWho this might be right forHLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS) Sarcoma Alliance for Research through Collaboration 47
Large-scale testing (Phase 3)Looking for participantsNCT05549297What this trial is testingTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Who this might be right forAdvanced Melanoma Immunocore Ltd 540
Testing effectiveness (Phase 2)Looking for participantsNCT06424340What this trial is testingMB-dNPM1-TCR.1 in Relapsed/Refractory AMLWho this might be right forLeukemia, Myeloid, Acute Miltenyi Biomedicine GmbH 29
Not applicableAvailableNCT04960891What this trial is testingA Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspWho this might be right forUveal Melanoma Immunocore Ltd
Testing effectiveness (Phase 2)UnknownNCT05549921What this trial is testingPhase II Study of TAEST16001 in Soft Tissue SarcomaWho this might be right forSoft Tissue Sarcoma Sun Yat-sen University 70
Early research (Phase 1)Looking for participantsNCT07156136What this trial is testingStudy of IMC-P115C in Advanced PRAME-Positive CancersWho this might be right forPRAME PositiveCancerHLA-A*02:01-positive Immunocore Ltd 140
Early research (Phase 1)Not Yet RecruitingNCT06358053What this trial is testingCRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced CancersWho this might be right forCervical CancerAnal CancerHead and Neck Cancers+1 more Corregene Biotechnology Co., Ltd 24
Early research (Phase 1)WithdrawnNCT05867056What this trial is testingStudy of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV InfectionWho this might be right forHepatitis B, Chronic Immunocore Ltd
Large-scale testing (Phase 3)Looking for participantsNCT06246149What this trial is testingAdjuvant Tebentafusp in High Risk Ocular MelanomaWho this might be right forUveal Melanoma European Organisation for Research and Treatment of Cancer - EORTC 290